<i><scp>CTLA</scp>‐4</i> polymorphism contributes to the genetic susceptibility of epithelial ovarian cancer

Chen, Juan; Kang, Shan; Wu, Jianlei; Zhao, Jian; Si, Wengang; Sun, Hongyu; Li, Yan

doi:10.1111/jog.15186

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no significant correlation was detected between the rs231775 G/A and rs3087243 G/A polymorphisms and susceptibility to EOC. The results confirmed that in women, the CTLA-4 rs5742909 C/T polymorphism may decrease the genetic predisposition to EOC ( 183 ).…”

Section: The Potential Of Antitumor Therapy On the Immune Microenviro...supporting

confidence: 79%

Recent advances in understanding the immune microenvironment in ovarian cancer

Chen,

Yang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The occurrence of ovarian cancer (OC) is a major factor in women’s mortality rates. Despite progress in medical treatments, like new drugs targeting homologous recombination deficiency, survival rates for OC patients are still not ideal. The tumor microenvironment (TME) includes cancer cells, fibroblasts linked to cancer (CAFs), immune-inflammatory cells, and the substances these cells secrete, along with non-cellular components in the extracellular matrix (ECM). First, the TME mainly plays a role in inhibiting tumor growth and protecting normal cell survival. As tumors progress, the TME gradually becomes a place to promote tumor cell progression. Immune cells in the TME have attracted much attention as targets for immunotherapy. Immune checkpoint inhibitor (ICI) therapy has the potential to regulate the TME, suppressing factors that facilitate tumor advancement, reactivating immune cells, managing tumor growth, and extending the survival of patients with advanced cancer. This review presents an outline of current studies on the distinct cellular elements within the OC TME, detailing their main functions and possible signaling pathways. Additionally, we examine immunotherapy rechallenge in OC, with a specific emphasis on the biological reasons behind resistance to ICIs.

show abstract

Section: The Potential Of Antitumor Therapy On the Immune Microenviro...supporting

confidence: 79%

Recent advances in understanding the immune microenvironment in ovarian cancer

Chen,

Yang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Another co-inhibitory molecule that plays a crucial role in OC progression and tumorigenesis is CTLA-4 [ 35 ]. It is a membrane protein expressed by activated T cells, constitutively regulatory T cells (Tregs), and is considered to be homologous to CD28, which is involved in the second step of T cell activation after the binding of an antigen and T cell receptor (TCR).…”

Section: Treatment Of Ovarian Cancermentioning

confidence: 99%

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors

Pawłowska

Rekowska

Kuryło

et al. 2023

IJMS

View full text Add to dashboard Cite

The standard treatment of ovarian cancer (OC) patients, including debulking surgery and first-line chemotherapy, is unsatisfactory because of recurrent episodes in the majority (~70%) of patients with advanced OC. Clinical trials have shown only a modest (10–15%) response of OC individuals to treatment based on immune checkpoint inhibitors (ICIs). The resistance of OC to therapy is caused by various factors, including OC heterogeneity, low density of tumor-infiltrating lymphocytes (TILs), non-cellular and cellular interactions in the tumor microenvironment (TME), as well as a network of microRNA regulating immune checkpoint pathways. Moreover, ICIs are the most efficient in tumors that are marked by high microsatellite instability and high tumor mutation burden, which is rare among OC patients. The great challenge in ICI implementation is connected with distinguishing hyper-, pseudo-, and real progression of the disease. The understanding of the immunological, molecular, and genetic mechanisms of OC resistance is crucial to selecting the group of OC individuals in whom personalized treatment would be beneficial. In this review, we summarize current knowledge about the selected factors inducing OC resistance and discuss the future directions of ICI-based immunotherapy development for OC patients.

show abstract

“…CTLA-4 is a T-cell inhibitory molecule who has a significant impact in carcinogenesis and progression [88]. CTLA-4 reduces the antitumor immune response mediated by T lymphocytes by inhibiting cytokine receptor signals, protein translation, triggering ubiquitin ligases, & mobilizing phosphatases [89].…”

Section: Cytotoxic T-lymphocyte Antigen-4 (Ctla-4)mentioning

confidence: 99%

Epithelial Ovarian Cancer: Microenvironment and Immunecheck Point Inhibitors

Kabala,

Bourhafour,

Chekrine

et al. 2023

EJMED

View full text Add to dashboard Cite

With poor prognosis for patients with advanced disease, ovarian cancer continues to be the most lethal gynecologic malignancy. Despite optimal treatment, the disease frequently recurs and develops chemoresistance. The tumor immune microenvironment has been predicted to play a special role in tumor development and treatment, by modifying immunosuppressive and cytotoxic responses in close proximity to tumor cells via metabolic reprogramming. A better understanding of the tumor microenvironment’s critical roles allows researchers to develop new therapeutic strategies, such as immunotherapy, to combat epithelial ovarian cancer chemoresistance. Unfortunately, the results of many clinical trials examining immune checkpoint blockade (ICB) have shown very low levels of efficacy for single-agent immune checkpoint inhibitors, and research on combination treatments has not yet identified any combinations with robust activity in a large number of epithelial ovarian cancer patients. The present research will begin with a review of the main concept of immune response inside the ovarian cancer microenvironment. Then, we’ll try to figure out what role various immune checkpoint inhibitors have in the ovarian cancer microenvironment. Finally, we’ll look into several exciting treatment options, such as immune checkpoint inhibition and the body’s anti-ovarian cancer immunological response.

show abstract

CTLA‐4 polymorphism contributes to the genetic susceptibility of epithelial ovarian cancer

Cited by 4 publications

References 27 publications

Recent advances in understanding the immune microenvironment in ovarian cancer

Recent advances in understanding the immune microenvironment in ovarian cancer

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors

Epithelial Ovarian Cancer: Microenvironment and Immunecheck Point Inhibitors

Contact Info

Product

Resources

About